Kameishi, Sumako
Dunn, Celia M.
Oka, Masatoshi
Kim, Kyungsook
Cho, Yun-Kyoung
Song, Sun U.
Grainger, David W.
Okano, Teruo
Article History
Received: 19 September 2022
Accepted: 11 March 2023
First Online: 17 March 2023
Competing interests
: S.K., M.O., K.K., and T.O. received compensation from an SCM research contract. Y.K.C. and S.U.S. hold equity in SCM Lifescience and are developers/inventors designated on intellectual property for clonal BMSC. T.O. holds equity in CellSeed, Inc. (Japan). No other competing financial interests exist, and all authors declare that they have no other competing interests.